Vertex Pharmaceuticals (VRTX) Hisse Fiyat
Vertex Pharmaceuticals Fiyat
Vertex Pharmaceuticals, son 19 yılda gelirini yıllık %23,6 artırarak 12,07 Md USD seviyesine taşıdı. Hisse başına kâr, son 14 yılda yıllık %40,3 büyüdü. Vertex Pharmaceuticals için net marj, %32,7 ile birkaç yıl önceki %30,9 seviyesine göre yükseldi. Vertex Pharmaceuticals için 12 aylık konsensüs fiyat hedefi 580,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %16,8 üzerinde bir seviyeye denk geliyor. 36 analistten 29 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Vertex Pharmaceuticals hisse senedi fiyatı
Vertex Pharmaceuticals iş modeli ve hisse analizi
Vertex Pharmaceuticals hakkında sık sorulan sorular
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analistler şu anda Vertex Pharmaceuticals hissesi için ortalama 553,08 USD hedef fiyat belirliyor (medyan: 580,00 USD); bu, son fiyata göre +11,3 % anlamına gelir. Konsensüs 36 analist notuna dayanır.
36 analist şu anda Vertex Pharmaceuticals hissesini değerlendiriyor: 29 al, 6 tut, 1 sat öneriyor. 2026 için analistler Vertex Pharmaceuticals şirketinin 13,25 Md USD gelir ve 18,47 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Vertex Pharmaceuticals hissesi 443,80 EUR (496,74 USD) seviyesindedir.
Vertex Pharmaceuticals hissesi (VRTX) 11 borsada işlem görür, bunlar arasında: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
beklenen'nin Vertex Pharmaceuticals hasılatı 13,25 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Vertex Pharmaceuticals karı 4,73 Md USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Vertex Pharmaceuticals'nin Fiyat/Kazanç (F/K) oranı şu anda 26,89'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Vertex Pharmaceuticals hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Vertex Pharmaceuticals'nin Fiyat/Satış (F/S) oranı şu anda 9,60'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Vertex Pharmaceuticals hisse senedinin değerleme metriği olarak hizmet eder.
Vertex Pharmaceuticals'nin Eulerpool Kalite Puanı 5/10'dur.
Vertex Pharmaceuticals'nin ISIN'i US92532F1003'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Vertex Pharmaceuticals'nin WKN'i 882807'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Vertex Pharmaceuticals'nin ticker'ı VRTX'dir. Ticker sembolü, Vertex Pharmaceuticals hisseleri borsada işlem görmek için kullanılır.
Vertex Pharmaceuticals Hissesi
Vertex Pharmaceuticals Emsaller Grubu
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
Vertex Pharmaceuticals'nin tüm temel göstergeleri ve derinlemesine analizi
Vertex Pharmaceuticals hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Vertex Pharmaceuticals şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: